Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Despite numerous clinical trials, it is unknown whether ethnicity affects treatment response to cognitive enhancers in Alzheimer's disease (AD). There is convincing evidence of ethnic and genetic variability in drug metabolism. This article reviews the available data on ethnicity in clinical trials for AD to answer two questions: (1) what are the challenges to diagnose and treat AD across different ethnic groups, and (2) are there differences in response to pharmacologic interventions for AD across these different ethnic groups? METHOD: Available data from Alzheimer's Disease Cooperative Study (ADCS) randomized controlled clinical trials and from randomized controlled industry-sponsored trials for four cognitive enhancers (donepezil, galantamine, rivastigmine and sabeluzole) were pooled to assess the numbers of non-Caucasian participants. RESULTS: The participation of ethnic minority subjects in clinical trials for AD was dependent on the funding source, although Caucasian participants were over-represented and non-Caucasian participants were under-represented in the clinical trials. Because of the low participation rate of ethnic minorities, there were insufficient data to assess any differences in treatment outcome among different ethnic groups. Strategies to improve diversity in clinical trials are discussed. CONCLUSION: Greater participation of ethnically diverse participants in clinical trials for AD would generate additional information on possible differences in metabolism, treatment response, adverse events to therapeutic agents, and could foster the investigation of genetic variability among ethnic groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 1×
“Alzheimer’s disease (AD) affects over 5 million people in the United States alone, with large increases in prevalence expected in the near future, both in the United States and around the world (Hebert et al., 2003, Alzheimer’s Association, 2007).”
BackgroundEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Acculturation, reading level, and neuropsychological test performance among African American elders
Manly, J. J., Byrd, D. A., Touradji, P., & Stern, Y. (2004) · Applied Neuropsychology · doi:10.1207/s15324826an1101_5 · Cited by 254
Self-citation
Cited by
More than Tuskegee: Understanding Mistrust about Research Participation
Scharff, D. P., Mathews, K. J., Jackson, P., Hoffsuemmer, J., Martin, E., & Edwards, D. (2010) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.0.0323 · Cited by 1,180
Babulal, G. M., Quiroz, Y. T., Albensi, B. C., Arenaza‐Urquijo, E., Astell, A. J., Babiloni, C., Bahar‐Fuchs, A., Bell, J., Bowman, G. L., Brickman, A. M., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.009 · Cited by 528
“[107] Faison WE, Schultz SK, Aerssens J, Alvidrez J, Anand R, Farrer LA, et al.”
BackgroundResultInfluentialSelf-citationA TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease
Roses, A. D., Lutz, M. W., Amrine-Madsen, H., Saunders, A. M., Crenshaw, D. G., Sundseth, S. S., Huentelman, M. J., Welsh-Bohmer, K. A., & Reiman, E. M. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.69 · Cited by 391
Cooper, C., Tandy, A. R., Balamurali, T. B. S., & Livingston, G. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181bf9caf · Cited by 311
Gilmore‐Bykovskyi, A. L., Jin, Y., Gleason, C., Flowers‐Benton, S., Block, L. M., Dilworth‐Anderson, P., Barnes, L. L., Shah, M. N., & Zuelsdorff, M. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.09.018 · Cited by 295
Metadata
- Authors
- Faison, W. E., Schultz, S. K., Aerssens, J., Alvidrez, J., Anand, R., Farrer, L. A., Jarvik, L., Manly, J., McRae, T., Murphy, G. M., Olin, J. T., Regier, D., Sano, M., & Mintzer, J. E.
- Venue
- International Psychogeriatrics
- Publisher
- Elsevier BV
- Published
- 2007-06
- Volume
- 19
- Issue
- 3
- Pages
- 539-558
- ISSN
- 1041-6102 (ISSN-L)
- OpenAlex
- W2128641262
- Cited by
- 76
- References
- 3
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. https://app.cochat.ai/papers/10.1017/s104161020700511x
- The paper
- Faison, W. E., Schultz, S. K., Aerssens, J., Alvidrez, J., Anand, R., Farrer, L. A., Jarvik, L., Manly, J., McRae, T., Murphy, G. M., Olin, J. T., Regier, D., Sano, M., & Mintzer, J. E. (2007). Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. International Psychogeriatrics. https://doi.org/10.1017/s104161020700511x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.